Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s current work centers on cancer treatments that act on the PAM pathway, including its lead therapeutic candidate gedatolisib, which is being developed for advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also operates a cellular analysis platform used to identify abnormal signaling activity in tumors and help guide the development of precision oncology therapies. Its business is concentrated in oncology drug development, with programs aimed at patients whose cancers are driven by specific molecular pathways. Headquartered in Minneapolis, Minnesota, Celcuity is positioned as a research-driven biotech company working across therapeutic development and biomarker-based cancer analysis.
Website16305 36th Avenue North
Minneapolis, MN, 55446
United States
Celcuity (CELC) has an average rating of buy and mean price target of $160.75, according to analysts
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on T
Investors talking about CELC also mention
| # | Name | Attention |
|---|---|---|
| 1 | IDEAYA Biosciences Inc.IDYA | 0%-0.01 |
| 2 | Abivax SAABVX | 0.01%-0.01 |
| 3 | Revolution Medicines, Inc.RVMD | 0.01%-0.01 |
| 4 | Crinetics Pharmaceuticals IncCRNX | 0%new |
| 5 | Elicio Therapeutics Inc.ELTX | 0%0 |
| 6 | Nuvalent, Inc.NUVL | 0%0 |
| 7 | HOUS - Anywhere Real Estate Inc. | —— |
| 8 | Smith Douglas Homes CorporationSDHC | 0%0 |
| 9 | Global Business Travel Group, Inc.GBTG | 0%new |
| 10 | STAI - ScanTech AI Systems Inc. | —— |
What share of all stock conversation is about CELC?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about CELC that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% 0 | 100% +25 | 66.67% -16.85 | 82.57% +5.16 | ||
| Bearish | 0% 0 | 0% -25 | 33.33% +16.85 | 17.43% -5.16 |
Of the messages about CELC that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 71.7% | 29.19% | ||
| Technical Analysis | — | 0% | 5.66% | 5.06% | ||
| Analysts | — | 0% | 22.64% | 23.84% | ||
| Earnings | — | 0% | 0% | 20.68% | ||
| Macro | — | 0% | 0% | 21.24% | ||
| Controversies | — | 0% | 0% | 0% |
Of the messages about CELC, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 20% | 71.11% | 47.89% | 41.94% | ||
| Newcomers | 80% | 28.89% | 52.11% | 58.06% |